Retatrutide
LY3437943
Retatrutide is a novel triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors for superior metabolic effects. This innovative approach produces enhanced appetite suppression, improved insulin sensitivity, and increased energy expenditure, potentially delivering 20-25% weight loss in clinical trials.
Complete Research Database
0
Major Studies
0
Total Participants
3
Research Articles
N/A
Years of Research
Safety Analysis
Adverse event data from clinical trials
Generally Well-Tolerated
Adverse Event Frequencies
Low (<10%)Moderate (10-25%)High (>25%)
42.1%
Highnausea
24.7%
Moderatevomiting
23.8%
Moderatediarrhea
19.3%
Moderateconstipation
18.5%
Moderateabdominal pain
12.4%
Moderateinjection site reactions
Clinical Safety Notes
Timing
GI side effects typically occur during dose escalation
Severity
Most adverse events are mild to moderate in severity
Adherence
Discontinuation rate due to side effects: ~5.3%
Safety
No increased risk of pancreatitis in clinical trials
Monitoring
Regular monitoring recommended for thyroid function
Medical Disclaimer
Retatrutide is currently in Phase 3 clinical trials and is not yet FDA approved. This information is for educational purposes only and should not replace medical advice. Consult with healthcare providers familiar with investigational therapies for personalized guidance. Side effects and contraindications are based on available clinical trial data.